Development of concomitant immunity in mice bearing the weakly immunogenic line 1 lung carcinoma
- PMID: 162863
Development of concomitant immunity in mice bearing the weakly immunogenic line 1 lung carcinoma
Abstract
The interaction between line 1 carcinomas growing s.c. and their spontaneous (or artificial) metastases has been studied in syngeneic BALB/c mice. In contrast to typical murine tumor systems, concomitant immunity, or the ability of primary tumors to suppress the growth of metastases, develops very slowly in this system, such that the metastases that are shed within the first week of tumor growth survive and ultimately prove lethal to the host. The rate of development of concomitant immunity can be accelerated by increasing the hosts' tumor burden or decelerated by exposure of the hosts to X-rays prior to tumor transplant. This cancer system offers, therefore, an excellent model for the therapy of metastases that cannot be obtained with typical murine tumors.
Similar articles
-
Specific and nonspecific stimulation of resistance to the growth and metastasis of the line 1 lung carcinoma.Cancer Res. 1975 Jan;35(1):242-4. Cancer Res. 1975. PMID: 1109793
-
A direct relationship between immune competence and the subcutaneous growth rate of a malignant murine lung tumor.Cancer Res. 1974 Apr;34(4):722-8. Cancer Res. 1974. PMID: 4360837 No abstract available.
-
Inhibition of subcutaneously growing line 1 carcinomas due to metastatic spread.Cancer Res. 1974 Aug;34(8):2005-10. Cancer Res. 1974. PMID: 4366938 No abstract available.
-
Concomitant tumor resistance: the role of tyrosine isomers in the mechanisms of metastases control.Cancer Res. 2012 Mar 1;72(5):1043-50. doi: 10.1158/0008-5472.CAN-11-2964. Epub 2012 Feb 7. Cancer Res. 2012. PMID: 22315349 Review.
-
Concomitant tumor resistance.Cancer Lett. 2012 Nov 28;324(2):133-41. doi: 10.1016/j.canlet.2012.05.021. Epub 2012 May 22. Cancer Lett. 2012. PMID: 22634498 Review.
Cited by
-
Further studies on antitumour responses induced by short-term pretreatment with syngeneic tumour cells.Br J Cancer. 1979 Feb;39(2):122-31. doi: 10.1038/bjc.1979.22. Br J Cancer. 1979. PMID: 219877 Free PMC article.
-
T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor.J Exp Med. 1980 Jan 1;151(1):69-80. doi: 10.1084/jem.151.1.69. J Exp Med. 1980. PMID: 6444236 Free PMC article.
-
T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites.J Exp Med. 1977 Feb 1;145(2):275-92. doi: 10.1084/jem.145.2.275. J Exp Med. 1977. PMID: 401860 Free PMC article.
-
"Concomitant immunity" in murine tumours of non-detectable immunogenicity.Br J Cancer. 1985 Jan;51(1):37-48. doi: 10.1038/bjc.1985.6. Br J Cancer. 1985. PMID: 2981538 Free PMC article.
-
Antitumour responses induced by short-term pretreatment with tumour cells.Br J Cancer. 1978 Feb;37(2):269-81. doi: 10.1038/bjc.1978.36. Br J Cancer. 1978. PMID: 629863 Free PMC article.